PGL-135
PGL-135 is a blood-brain barrier-permeable Huntingtin aggregation inhibitor. PGL-135 is applicable to research related to Huntington's disease.
For research use only. We do not sell to patients.
- CAS No.: 26278-83-1
- Formula: C9H10N2OS
- Molecular Weight:194.25
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
PGL-135 (25-50 μM) inhibits the aggregation of HDQ51 in 293 Tet-Off cells expressing HDQ51, with an IC50 of 40 μM; it reduces inclusion body formation by 30% at a concentration of 25 μM and by 50% at 50 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:hemizygote R6/2 (female, 10-11 weeks old, CBA × C57BL/6 F1 background); wild-type littermates (female, 10-11 weeks old, CBA × C57BL/6 F1 background)[1]
-
Dosage:30 mg/kg
-
Administration:i.p.; single dose
-
Result:Was detectable in micromolar concentrations in brain and serum during the first 30 minutes post-injection.
Was virtually undetectable by 40 minutes post-injection.
Was not reliably detectable in liver at any time point.
Chemical Information
-
CAS No. 26278-83-1
-
Molecular Weight 194.25
-
Formula C9H10N2OS
-
SMILES
OC1=CC(=C2N=C(SC2=C1C)N)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)